Blog Stats
- 150,251 hits
www.friedmanconsultingllc.com
Blogroll
TUNGSTEN SHIELD WEBINARS
Warning Letters
-
Recent Posts
- A REVIEW OF AN EXTENSIVE ENDOTOXIN WARNING LETTER USING THE NEW FDA “ENDOTOXIN” Q&A AS A BACKDROP
- Mylan Laboratories, India Receives Warning Letter (08/06/2015)
- Quality Metrics and Risk Based Inspections
- FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014
- 2015 United States Pharmacopeia (USP) Microbiological General and Information Chapters Training Program
Archives
- August 2015
- July 2015
- June 2015
- April 2015
- March 2015
- February 2015
- December 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
Categories
- 483
- Adverse Determination Letter
- Compounding Pharmacy
- Consent Decree
- Dietary Supplements
- FDA Compliance
- Import Alert
- Import Ban
- Microbiological Issues
- New Guidances for Industry
- On-Site Training
- Permanent Injunction
- Positron Emission Tomography (PET)
- Purpose and Scope
- Recall
- Regulatory Compliance
- Seizure
- Uncategorized
- Warning Letters
- Webinar
Pages
-
Join 7 other subscribers
- 21 CFR 211
- 21 CFR 211.192
- 211.113(a)
- 211.113(b)
- 211.192
- Accugenix
- Annex 1
- API
- Aseptic Processing
- Bacillus
- Bacillus cereus
- bacteria
- bacterial contamination
- B cepacia
- Ben Venue
- Ben Venue Laboratories
- BVL
- CAPA
- CDER
- CMO
- Consent Decree
- contamination
- DNA Sequencing
- drug shortages
- endotoxin
- Environmental Monitoring
- FDA
- FDA 483
- FDA 483s
- FDA Compliance
- Form FDA 483
- GMP
- GMP Training
- Growth Promotion
- Guidance for Industry
- H&P Industries
- H & P Industries
- HEPA filters
- Hospira
- import alert
- injectables
- interventions
- Johnson & Johnson
- McNeil-PPC
- media fills
- microbial contamination
- Microbiological Contamination
- NECC
- non-sterility
- Objectionable microorganisms
- Observations
- OOS
- PDI
- Permanent Injunction
- Process Validation
- Puerto Rico
- purified water
- Ranbaxy
- Recall
- Risk Assessment
- seizure
- specifications
- Specified microorganisms
- sterile drug products
- Sterility
- Sterility Test
- Sterility Tests
- training
- Triad Group
- USP
- USP 61
- USP 62
- Validation
- Warning Letter
- Warning Letters
Meta
Tag Archives: rejected batches
JUBILANT HOLLISTERSTIER RECEIVES WARNING LETTER (2/13/13)
ASEPTIC FILLING FACILITY RECEIVES SIGNIFICANT OBSERVATIONS Jubilant HollisterStier located in Kirkland, Quebec, Canada was audited by the FDA on March 19-26, 2012. Following the receipt of the Form FDA 483, the Company responded on April 13, 2012 to the Observations … Continue reading
Barry A Friedman, PhD LLC 